Receptor News and Research

RSS

Researchers identify key differences between two subtypes of chronic lymphocytic leukemia

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic leukemia, CLL.

18 Nov 2025

Brain recordings reveal short-lived effects of tirzepatide on food cravings

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" thought to be involved in food noise – but only temporarily.

17 Nov 2025

Breast cancer cells use a molecular switch to survive stress

Cells are regularly faced with environmental stresses that may damage or destroy them. To survive, they quickly adjust their gene expression to protect themselves.

17 Nov 2025

Red meat raises inflammation marker CRP in clinical trials

The review analyzes red meat's effects on inflammatory biomarkers, revealing significant associations with CRP in specific adult subgroups and dietary contexts.

17 Nov 2025

Gut microbes may fuel allergic rhinitis symptoms

The study identifies gut microbiome alterations in allergic rhinitis, suggesting a gut-nose axis that could inform new treatment approaches for this condition.

17 Nov 2025

DeepTarget: A new tool for drug repurposing in oncology

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

14 Nov 2025

MD Anderson launches historic $2.5 billion campaign to end cancer

The University of Texas MD Anderson Cancer Center today launches its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer.

14 Nov 2025

Understanding leptin's dual function in MAFLD pathogenesis

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with obesity, type 2 diabetes (T2DM), and metabolic syndrome.

14 Nov 2025

Hypertension may induce early gene expression changes in brain cells

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell Medicine investigators.

14 Nov 2025

New technique revolutionizes the design of drugs that target ion channels

An international team involving the Institute of Chemical Research, a joint centre of the University of Seville and the Spanish National Research Council, has developed a new technique that will accelerate the design of drugs that target ion channels, a type of cell membrane protein involved in numerous diseases, ranging from psychiatric disorders to various types of cancer.

14 Nov 2025

Enhancing the cancer-immunity cycle through innovative vaccines

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies.

14 Nov 2025

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains. This perspective maps how such pharmacological thinness interacts with stigma, beauty ideals, digital culture, and inequality, and calls for multinational, intersectional research to understand its full impact.

13 Nov 2025

Scientists reveal how prolonged UV exposure weakens cellular defense against skin cancer

Sunlight is vital for human health as it helps the body produce essential nutrients, such as vitamin D. However, too much sun exposure can significantly increase the risk of skin cancer.

13 Nov 2025

Single-cell study reveals how HPV shapes immune landscape in penile cancer

Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden, with a five-year survival rate near 50%.

13 Nov 2025

Innovative research reveals FGD3 as a key player in breast cancer cell death

A naturally occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report.

13 Nov 2025

Switching APOE4 to APOE2 in adult mice reduces Alzheimer’s pathology and improves memory

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is complete. This switch, especially when targeted to astrocytes, reduces amyloid burden, dampens gliosis, and improves associative memory despite E2-like peripheral lipid risks.

12 Nov 2025

Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension (PH) being a primary driver of disease progression and decompensation.

12 Nov 2025

Discovery of 'Mann-type DLBCL' offers hope for more targeted cancer therapies

Researchers at the University of Southampton have identified a new subtype of lymphoma which could pave the way to improved and more targeted treatments for some blood cancer patients.

11 Nov 2025

The caffeine conundrum in rapid depression treatments

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine as the critical mediator, yet adenosine receptors are the primary target of caffeine, the world's most widely consumed psychoactive substance.

11 Nov 2025

GLP-1 drugs linked to improved survival in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar and weight.

11 Nov 2025